Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight Ji Hye MinHo Yun LeeKyung Soo Lee Mini Review 13 September 2011 Pages: 1099 - 1109
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study Keith T. FlahertyChetan LathiaPeter J. O’Dwyer Original Article 25 February 2011 Pages: 1111 - 1118
Phase I trial of metronomic oral vinorelbine in patients with advanced cancer Lakshmi RajdevAbdissa NegassaJoseph A. Sparano Original Article 04 March 2011 Pages: 1119 - 1124
The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats V. Ashutosh RaoJun ZhangEmily B. Shacter Original Article 04 March 2011 Pages: 1125 - 1134
Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma Martha RomeroJosette BrièreAnne Janin Original Article 05 March 2011 Pages: 1135 - 1143
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea Bret BannermanLing XuAllison Berger Original Article Open access 13 March 2011 Pages: 1145 - 1154
Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia Meryem AlbayrakUljan KonyssovaUlker Kocak Original Article 13 March 2011 Pages: 1155 - 1159
Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells Davide StaedlerElita IdriziLucienne Juillerat-Jeanneret Original Article 13 March 2011 Pages: 1161 - 1172
First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group Uwe PelzerDirk ArnoldHelmut Oettle Original Article 15 March 2011 Pages: 1173 - 1178
Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein Howard R. MellorRichard Callaghan Original Article 15 March 2011 Pages: 1179 - 1190
Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases Romain GuilhaumouNicolas SimonCaroline Solas Original Article 14 December 2010 Pages: 1191 - 1198
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer Jianguo ZhiEric ChenDavid Goldstein Original Article 16 March 2011 Pages: 1199 - 1206
Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients Alfonso De StefanoChiara CarlomagnoSabino De Placido Original Article 16 March 2011 Pages: 1207 - 1213
Phase II study of FOLFOX4 with “wait and go” strategy as first-line treatment for metastatic colorectal cancer Mitsugu KochiWataru IchikawaToshifusa Nakajima Original Article 17 March 2011 Pages: 1215 - 1222
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis Claudia LebedinskyJavier GómezCarmen Kahatt Original Article 18 March 2011 Pages: 1223 - 1231
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors George R. SimonRobert L. Ilaria Jr.David R. Spriggs Original Article Open access 23 March 2011 Pages: 1233 - 1241
A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19F NMR spectroscopy Tashinga E. BapiroFrances M. RichardsDuncan I. Jodrell Original Article Open access 23 March 2011 Pages: 1243 - 1253
Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer William C. ZamboniAustin J. CombestJoseph L. Kelley Original Article 25 March 2011 Pages: 1255 - 1262
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer In Hae ParkYeon-Su LeeByung-Ho Nam Original Article 27 March 2011 Pages: 1263 - 1271
Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival Austin M. GuoXiuli LiuAdnan R. Munkarah Original Article 29 March 2011 Pages: 1273 - 1283
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function Jeong Eun KimBaek-Yeol RyooYoon-Koo Kang Original Article 29 March 2011 Pages: 1285 - 1290
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer Hernan CarolIngrid BoehmRichard B. Lock Original Article Open access 30 March 2011 Pages: 1291 - 1304
Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy N. CézéG. ThibaultT. Lecomte Original Article 30 March 2011 Pages: 1305 - 1313
Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells Ying-Wei LiGuo-Yuan ZhuWang-Fun Fong Original Article 03 April 2011 Pages: 1315 - 1323
Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases Masako AsayamaNozomu FuseAtsushi Ohtsu Original Article 03 April 2011 Pages: 1325 - 1330
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion Paul K. PaikLeonard P. JamesNaiyer A. Rizvi Original Article 03 April 2011 Pages: 1331 - 1337
Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants Velia D’AngeloMaria RamagliaFiorina Casale Original Article 18 May 2011 Pages: 1339 - 1346
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy S. PignataF. AmantI. Vergote Clinical Trial Report 10 September 2011 Pages: 1347 - 1353
Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation E. GiorgioC. CarotiE. Di Maria Short Communication 11 August 2011 Pages: 1355 - 1361
Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease Juliette ThariatMarie-Christine Etienne-GrimaldiAntoine Thyss Short Communication 18 August 2011 Pages: 1363 - 1367
MTHFR 677TT genotype and toxicity of methotrexate: controversial results Elixabet Lopez–LopezJavier BallesterosAfrica Garcia-Orad Letter to the Editor 06 August 2011 Pages: 1369 - 1370
